375 related articles for article (PubMed ID: 16087126)
1. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
3. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
[TBL] [Abstract][Full Text] [Related]
7. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C.
Panasiuk A; Parfieniuk A; Zak J; Flisiak R
Liver Int; 2010 Mar; 30(3):472-8. PubMed ID: 19919570
[TBL] [Abstract][Full Text] [Related]
8. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
9. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
Lapinski TW; Jaroszewicz J; Wiercinska-Drapalo A
Viral Immunol; 2006; 19(3):570-5. PubMed ID: 16987075
[TBL] [Abstract][Full Text] [Related]
11. Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-alpha in periarticular tenocytes from patients with knee joint osteoarthritis.
Machner A; Baier A; Wille A; Drynda S; Pap G; Drynda A; Mawrin C; Bühling F; Gay S; Neumann W; Pap T
Arthritis Res Ther; 2003; 5(5):R253-61. PubMed ID: 12932288
[TBL] [Abstract][Full Text] [Related]
12. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
13. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of ssDNA in liver tissue and its correlation with sFas and sFasL in serum of patients infected with HBV, HCV, HCV and HIV.
Łapinski TW; Wiercińska-Drapało A; Panasiuk A; Kovalchuk O
Adv Med Sci; 2007; 52():109-13. PubMed ID: 18217400
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
Zaki Mel S; Auf FA; Ghawalby NA; Saddal NM
Immunol Invest; 2008; 37(2):163-70. PubMed ID: 18300041
[TBL] [Abstract][Full Text] [Related]
16. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
17. [Concentrations of soluble factors participating in regulation of apoptosis of lymphocyte from patients with chronic lyme arthritis (preliminary report)].
Grygorczuk S; Zajkowska J; Swierzbińska R; Pancewicz S; Kondrusik M; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2006 Jan; 20(115):49-52. PubMed ID: 16617735
[TBL] [Abstract][Full Text] [Related]
18. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma.
Mezei G; Lévay M; Sepler Z; Héninger E; Kozma GT; Cserháti E
Pediatr Allergy Immunol; 2006 Sep; 17(6):444-9. PubMed ID: 16925690
[TBL] [Abstract][Full Text] [Related]
19. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis.
Tokushige K; Yamaguchi N; Ikeda I; Hashimoto E; Yamauchi K; Hayashi N
Am J Gastroenterol; 2000 Aug; 95(8):2040-6. PubMed ID: 10950055
[TBL] [Abstract][Full Text] [Related]
20. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
